Skin Vaccination Summit 2017

22-24 May 2017, Leiden University Medical Centre, Leiden, The Netherlands

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Wednesday 24th May 2017

SESSION 9:
DELIVERY II

Moderator: Mark Tomai (3M Company, St. Paul, Minnesota, USA)

09.00-09.20
‘Overview of development of microneedle patches with Inactivated Poliovirus Vaccine (IPV)’
Shanda Boyle1 and Hiromasa Okayasu2 (1 Bill & Melinda Gates Foundation, Seattle, Washington, USA; 2 Polio Eradication Department, World Health Organization, Geneva, Switzerland)

09.20-09.50
‘Transitioning delivery of inactivated poliovirus vaccine by the Nanopatch from pre-clinical studies to clinical trials’
David A. Muller1,2, Germain Fernando2, Paul R. Young2, Paul Fahey3 and Angus Forster3 (1 Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia; 2 School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia; 3 Vaxxas Pty Ltd, Sydney, New South Wales, Australia)

09.50-10.20
‘HIV enzyme interactions in combined intradermal DNA immunization in mice’
Maria G. Isaguliants1,2,3 (1 A. Kirchenstein Institute of Microbiology and Virology, Riga Stradins University (RSU), Riga, Latvia; 2 Chumakov Federal Scientific Center for Research and Development of Immunobiological Preparations, Moscow, Russia; 3 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden)

10.20-10.50
‘Tracking nanoparticles from top to the bottom: Uptake behavior of Chitosan-PLGA nanoparticles within the skin structure’
Hanzey Yasar1, Simon Delandre2, Chiara De Rossi1, Kai Schulze2, Brigitta Loretz1, Sarah Gordon3, Andreas Müller4, Carlos A. Guzman2 and Claus-Michael Lehr1 (1 Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) and Helmholtz Centre for Infection Research (HZI), Department of Drug Delivery, Saarbruecken, Germany; 2 Helmholtz Centre for Infection Research (HZI), Department of Vaccinology and Applied Microbiology, Braunschweig, Germany; 3 School of Pharmacy and Biomolecular Sciences, James Parsons Building Tower, Byrom Street, Liverpool, UK; 4 Otto-von-Guericke University of Magdeburg (OVGU), Magdeburg, Germany)

10.50-11.30
Coffee Break & Posters

SESSION 10:
DELIVERY III

Moderator: Anne Moore (University College Cork, Cork, Ireland)

11.30-11.50
‘Tight junction inhibition as a transdermal vaccine delivery strategy’
Matthew G Brewer, Elizabeth Anderson, Benjamin Miller and Lisa Beck (University of Rochester, Rochester, New York, USA)

11.50-12.10
‘Prophylactic intradermal delivery of INO-4201 drives robust ebola glycoprotein specific humoral and cellular Immune responses in healthy volunteers in an open label phase I trial’
Jean Boyer and Kate E. Broderick (Inovio Pharmaceuticals, San Diego, California, USA)

12.10-12.30
‘Importance of assessment of skin thickness in healthy children aged 8 weeks to 18 years in development of intradermal drug delivery devices’
Timothi Van Mulder (Novosanis NV, Wijnegem, Belgium)

12.30-14.00
Lunch Break & Posters Breakdown

SESSION 11:
LATE-BREAKER PRESENTATIONS

Moderators: Joke Bouwstra and Bram Slutter (Leiden/Amsterdam Center for Drug Research, Amsterdam, The Netherlands)

14.00-14.20
‘Role of alternative reading frame protein in the immune response to HCV core, evaluation by intradermal DNA-immunization in mice’
Juris Jansons1,2, Anastasija Dovbenko2, Dace Skrastina2, Stefan Petkov3, Elizaveta Starodubova3,4,5, Yulia Kuzmenko4, Gatis Akmenkalns2, Maria G. Isaguliants1,3,6 and Irina Sominskaya2 (1 Riga Stradins University, Riga, Latvia; 2 Latvian Biomedical Research and Study Center, Riga, Latvia; 3 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; 4 WA Engelhardt Institute of Molecular Biology, Moscow, Russia; 5 Chumakov Institute of Poliomyelitis and Viral Encephalitides, Moscow, Russia; 6 Gamaleya Research Center of Epidemiology and Microbiology, Moscow, Russia)

14.20-14.40
‘Tuberculin skin test (TST) using dissolving microneedle fabricated by centrifugraphy’
Hyungil Jung (Yonsei University, Seoul, Korea)

14.40-15.00
‘Experimental vaccine protects against hepatitis E virus genotypes 1 and 3 in non-human primate model’
Ilya V. Gordeychuk1,2, Alexey M. Chumakov1, Anna A. Lyashenko1, Alexey A. Sorokin1, Stanislav A. Gulyaev1, Ilya A. Potemkin3, Amir I. Tukhvatulin2, Denis Y. Logunov2, Anastasia A. Karlsen3, Olga V. Isaeva3, Karen K. Kyuregyan3 and Mikhail I. Mikhailov3 (1 Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences, Moscow, Russia; 2 Gamaleya Research Center for Epidemiology and Microbiology, Ministry of Healthcare of the Russian Federation, Moscow, Russia; 3 Research center at Russian Medical Academy of Postgraduate Education, Ministry of Healthcare of the Russian Federation, Moscow, Russia)

15.00-15.15
‘Alternative reporters for monitoring the success of intradermal DNA delivery and expression in a mouse model’
Laura Hippe1, Martins Kalis1, Ilya Gordeychuk2,3, Stefan Petkov3, Maksim Abakumov4, Daria Shcherbakova5, Vladislav Verkhusha5 and Maria G. Isaguliants1,2,3 (1 A. Kirchenstein Institute of Microbiology and Virology (AKMVI), Riga Stradins University (RSU), Riga, Latvia; 2 Gamaleja Research Center of Epidemiology and Microbiology, and Chumakov Federal Scientific Center for Research and Development of Immunobiological Preparations, Moscow, Russia; 3 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; 4 The Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia; 5 Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY, USA)

15.15-15.30
‘Administration of different Toll like receptor agonists by dissolving microneedle patches to pigs: Assessment of local immune response by macroscopic and histologic evaluation’
Sandra Vreman1, Joanne McCafferey2, Norbert Stockhofe-Zurwieden1 and Anne Moore3 (1 Wageningen Bioveterinary Research, Wageningen University & Research, The Hague, The Netherlands; 2 Xeolas, Pharmaceuticals, Dublin, Ireland; 3 School of Pharmacy University College Cork, Cork, Ireland)

15.30-15.45
‘Stable expression of HIV reverse transcriptase by murine adenocarcinoma cells enhances growth rate of primary tumors in a mouse model designed to test the therapeutic efficacy of HIV DNA vaccines’
E. Pankova1,2, A. Latanova1,2,3, A. Kilpelainen3,4, I. Gordeychuk2,3,5, S. Petkov3, M. Abakumov4, E. Starodubova1,3,5 and M. Isaguliants2,3,5,6 (1 Engelhardt Institute of Molecular Biology, Moscow, Russia; 2 Gamaleja Research Center of Epidemiology and Microbiology, Moscow, Russia; 3 Karolinska Institutet, Stockholm, Sweden; 4 Pirogov Medical State University, Moscow, Russia; 5 Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences, Moscow, Russia; 6 Riga Stradins University, Riga, Latvia)

15.45
Conference Close & Departure

* This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

 

SVS 2017 Delegates

Login details will be supplied after you have registered for the event.


SVS 2017 Sponsors

  • Debiotech
  • Nanopass
  • VisMederi
  • Novosanis
  • CIMI
  • Becton Dickinson
  • PATH
  • DNAvaccine.com
  • NatureGeneTherapy.com
  • Univac
  • Star Syringe
  • Novartis Vaccines
  • ONdrugDELIVERY
  • Inovio
  • Pantec Biosolutions
  • Corium
  • 3M
  • IDRI
  • West
  • Sanofi Pasteur
  • Swiss Vaccine
  • Aldevron

SVS 2017 Downloads

SVS 2017 Leaflet

SVS 2017 Mailing List

Name
E-mail Address
What is 3+2-1?